Takeda Pharmaceutical (NYSE:TAK) Releases FY 2026 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 3.009-3.009 for the period, compared to the consensus EPS estimate of 1.570. The company issued revenue guidance of $29.6 billion-$29.6 billion, compared to the consensus revenue estimate of $29.0 billion.

Analysts Set New Price Targets

TAK has been the subject of several research reports. Wall Street Zen upgraded Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 11th. Morgan Stanley assumed coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Takeda Pharmaceutical in a report on Wednesday, April 29th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $16.43 on Wednesday. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $18.90. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65. The company has a market cap of $52.28 billion, a PE ratio of 68.44 and a beta of -0.06. The stock’s 50 day simple moving average is $17.68 and its 200-day simple moving average is $16.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TAK. Parkside Financial Bank & Trust lifted its holdings in Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after buying an additional 1,684 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after purchasing an additional 2,328 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $74,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at about $101,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.